Integration of models and experimentation to optimise the production of potential biotherapeutics.

Highlights: [•] Lead optimisation, preclinical development and clinical trials are the most costly stages of drug development. [•] Predicting manufacturing challenges can expedite and reduce costs of development. [•] Computational models can instruct the design of a therapeutic protein. [•] Mechanistic models are useful instruments in the design of a bioprocess. [•] Analytics available on- or at-line are facilitating the application of modelling. [ABSTRACT FROM AUTHOR]